MGC Pharmaceutical receives Health Canada approval

Published at May 30, 2016, in Biotech

Following on from last week’s news that MGC Pharmaceutical (ASX:MXC) had received FDA approval to sell and distribute its CBD-based cosmetic products across the US, comes the news that Health Canada has also given MGC Pharmaceuticals regulatory approval.

Health Canada approval enables MGC Pharmaceuticals to pursue distribution and sales agreements in a market estimated to be $US1.9 billion.

MGC Pharmaceuticals is currently in negotiations on distribution agreements in Canada to facilitate sales into this key market.

The Canadian market is a leader in the global medicinal field, and with pharmaceutical ambitions as well as a retail agenda, approval in this region is critical to MGC Pharmaceutical’s long-term business plan.

“MGC Pharmaceuticals has moved forward with its commercialisation strategy for its CBD cosmetics range at a rapid pace, delivering key regulatory approvals, distribution agreements and commencing sales in recent months,” said MGC Pharmaceuticals co-founder and managing director Nativ Segev.

“Our approval from Health Canada is another strong step forward, enabling us to expand our geographic sales reach for the products into Canada, which has a very progressive attitude and legislation for medicinal cannabis and related product markets.

MGC Pharmaceuticals has now managed to gain approval from the FDA in the US, the European Commission’s Cosmetic products Notification Portal (CPNP) for its cosmetics product line.

The company is also awaiting approval in Australia from the Australian Therapeutic Good Administration (TGA).

It is expected the TGA will hand down its decision shortly. If favourable, MGC Pharmaceuticals would be able to sell the cosmetics product line to Australian consumers and MXC’s shareholders.

S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.

Conflict of Interest Notice

S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.

Publishers Notice

The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.

Facebook
Twitter
LinkedIn